What is new in pericytomatous, myoid, and myofibroblastic tumors?

Virchows Arch. 2020 Jan;476(1):57-64. doi: 10.1007/s00428-019-02700-y. Epub 2019 Nov 8.

Abstract

Recent advances in molecular techniques in soft tissue pathology, including the widespread application of next-generation sequencing, have led to significant progress in our understanding of mesenchymal tumors. Recognition of the genetic signatures of these neoplasms not only clarifies the relationship of these entities but also provides a mechanism for more accurate diagnosis. More importantly, insight into the genetic underpinnings of these lesions may offer therapeutic targets for cases not amenable to surgical treatment. This review highlights the clinicopathologic features and novel molecular findings in pericytic, myoid, and myofibroblastic tumors.

Keywords: Calcifying aponeurotic fibroma; Fibrous hamartoma of infancy; GLI1; Lipofibromatosis; PDGFRB; Pericytic neoplasms; SRF-RELA.

Publication types

  • Review

MeSH terms

  • Fibroma / genetics
  • Fibroma / pathology*
  • Gene Rearrangement
  • Humans
  • Myofibroma / genetics
  • Myofibroma / pathology
  • Neoplasms, Connective and Soft Tissue / genetics
  • Neoplasms, Connective and Soft Tissue / pathology*
  • Pericytes / pathology*
  • Proto-Oncogene Proteins B-raf / genetics
  • Proto-Oncogene Proteins p21(ras) / genetics
  • Receptor, Platelet-Derived Growth Factor beta / genetics
  • Zinc Finger Protein GLI1 / genetics

Substances

  • GLI1 protein, human
  • KRAS protein, human
  • Zinc Finger Protein GLI1
  • Receptor, Platelet-Derived Growth Factor beta
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • Proto-Oncogene Proteins p21(ras)